Abstract
Cytoreductive surgeries (CRSs) are the common management modality for advanced cancers. The perioperative period is impacted by major surgical resection and its associated effects. The surgical morbidity is further enhanced when the resection of abdominal and thoracic cavity is required simultaneously. It is added on by the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) and hyperthermic intrathoracic chemotherapy (HITHOC). These procedures are technically challenging with potential for high perioperative morbidity and mortality. We report a case of 56-year-old female diagnosed with carcinoma ovary with pleural metastases and malignant right pleural effusion and scheduled for CRS with HIPEC together with HITHOC.